Citadel Advisors’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-261,200
| Closed | -$6.17M | – | 15732 |
|
|
2023
Q4 | $6.17M | Buy |
261,200
+138,800
| +113% | +$2.47M | ﹤0.01% | 3510 |
|
|
2023
Q3 | $1.82M | Buy |
122,400
+69,500
| +131% | +$921K | ﹤0.01% | 5384 |
|
|
2023
Q2 | $579K | Buy |
52,900
+15,300
| +41% | +$142K | ﹤0.01% | 7618 |
|
|
2023
Q1 | $328K | Sell |
37,600
-55,700
| -60% | -$446K | ﹤0.01% | 9198 |
|
|
2022
Q4 | $585K | Buy |
93,300
+19,600
| +27% | +$74.5K | ﹤0.01% | 7917 |
|
|
2022
Q3 | $258K | Sell |
73,700
-14,700
| -17% | -$52.8K | ﹤0.01% | 9906 |
|
|
2022
Q2 | $261K | Buy |
88,400
+20,400
| +30% | +$48.7K | ﹤0.01% | 10130 |
|
|
2022
Q1 | $211K | Sell |
68,000
-300
| -0.4% | -$944 | ﹤0.01% | 11406 |
|
|
2021
Q4 | $231K | Buy |
68,300
+32,100
| +89% | +$122K | ﹤0.01% | 11553 |
|
|
2021
Q3 | $132K | Buy |
36,200
+7,800
| +27% | +$30.7K | ﹤0.01% | 12533 |
|
|
2021
Q2 | $124K | Buy |
28,400
+300
| +1% | +$1.33K | ﹤0.01% | 12717 |
|
|
2021
Q1 | $128K | Sell |
28,100
-17,400
| -38% | -$93.6K | ﹤0.01% | 12228 |
|
|
2020
Q4 | $261K | Buy |
45,500
+18,900
| +71% | +$143K | ﹤0.01% | 9319 |
|
|
2020
Q3 | $193K | Buy |
26,600
+2,700
| +11% | +$14.4K | ﹤0.01% | 8837 |
|
|
2020
Q2 | $83K | Buy |
23,900
+6,500
| +37% | +$18.8K | ﹤0.01% | 9093 |
|
|
2020
Q1 | $26K | Sell |
17,400
-60,900
| -78% | -$102K | ﹤0.01% | 9234 |
|
|
2019
Q4 | $153K | Sell |
78,300
-52,600
| -40% | -$198K | ﹤0.01% | 8353 |
|
|
2019
Q3 | $670K | Buy |
130,900
+36,500
| +39% | +$221K | ﹤0.01% | 6253 |
|
|
2019
Q2 | $676K | Buy |
+94,400
| New | +$1.07M | ﹤0.01% | 6331 |
|
Other funds holding CBAY
Citadel Advisors's CBAY Position: Q1 2024 in Review
Citadel Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 330,234 shares — an estimated $7.8M sold.
Citadel Advisors first reported a position in CBAY in Q1 2015 and held it in 31 quarters. The position peaked at $37.3M in Q1 2019. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Citadel Advisors reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Citadel Advisors sold 330,234 Cymabay Therapeutics shares in Q1 2024, an estimated $7.8M.
- Citadel Advisors first reported a position in Cymabay Therapeutics in Q1 2015 and held it in 31 quarters.
- Citadel Advisors's Cymabay Therapeutics position peaked at $37.3M in Q1 2019.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.